Drugs whose prices have been reduced by the Medicare negotiation process established by the Inflation Reduction Act will not be subject to additional new discounts required in Part D as part of the law’s overhaul of the benefit design.
Medicare Part D Redesign: New Discounts Will Not Apply To Drugs With ‘Negotiated’ Prices
However, Part D drugs subject to government price setting under the Inflation Reduction Act will still face pharmacy benefit manager demands for additional rebates in return for preferential formulary status.
More from Pricing Debate
More from Market Access
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.